DOCSLIB.ORG

2019Insar Program Bk.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

2019 Sponsors We thank the following organizations for their generous support of INSAR and the Annual Meeting. Platinum Sponsor Level Gold Sponsor Level Silver Sponsor Level Autism Science Foundation Hilibrand Foundation Nancy Lurie Marks Family Foundation TABLE OF CONTENTS Sponsorship .................................Inside Front Cover TABLE OF CONTENTS Sensory Break Room ............................................ 6 Special Interest Groups Schedule .......................... 6 Speaker Ready Room ............................................ 6 Meeting Information INSAR Business Meeting ...................................... 6 Palais des congres de Montreal Floor Plans ......... 7-8 Schedule At A Glance ...................................... 9-12 WIFI CONNECTION In-Conjunction Events .................................... 13-14 Connect to the Keynote Speakers .............................................. 15 network 2019 INSAR Fellows ........................................... 16 INSAR Awardees ..................................................... 17-19 Enter the Password Acknowledgments .......................................... 20-21 MONTREAL19 2019 INSAR Institute ........................................ 22 AM Keynote Address ................................................ 23 INSAR 365 MOBILE APP Panel Sessions .............................................. 23-26 THURSDAY Poster Sessions ............................................ 26-52 PM MAY 2 Oral Sessions ............................................... 52-56 Awards Ceremony .............................................. 57 Keynote Address ................................................ 57 Poster Sessions ............................................ 57-81 Step 1 - Download Chameleon AM http://meaurl.com/chameleon Special Interest Groups (SIGs) ............................ 83 Keynote Address ................................................ 83 Panel Sessions .............................................. 84-86 FRIDAY Technology Demonstrations/Posters ............... 87-88 Poster Sessions .......................................... 88-111 MAY 3 PM Oral Sessions ........................................... 111-115 Panel Sessions .......................................... 115-118 Keynote Speaker .............................................. 118 Poster Sessions ........................................ 118-143 AM Special Interest Groups (SIGs) .......................... 145 Step 2 - Type ‘INSAR’ in the SATURDAY Keynote Address .............................................. 145 Search Field Panel Sessions .......................................... 146-149 MAY 4 Step 3 - Choose INSAR from Poster Sessions ........................................ 149-174 the List PM Panel Sessions .......................................... 174-177 Connect with Other Attendees Author Abstract Index ............................... 179-266 Use the Connect feature to General Information ................................... 267-268 communicate with other INSAR Exhibitors ................................................. 269-270 Annual Meeting attendees. Note that some registrants opted out of Follow us on Twitter: @AutismINSAR being included in Connect. Join the conversation: #AutismINSAR #INSAR2019 ‘Connect’ password: INSAR2019Mobile https://www.facebook.com/AutismINSAR 1 INSAR WELCOME Welcome to Canada and Montreal for the 2019 International Society for Autism Research Annual Meeting (INSAR 2019). Montreal is a vibrant, multicultural city, making it an ideal venue for such a diverse group of international delegates. Over 2,000 abstracts from all over the world were submitted, reflecting the diversity of research in ASD, from neuroscience and molecular genetics to psychology, medicine, technology, and lived-experience research, to name a few. Congratulations to all awardees, whose research exemplifies the exceptional quality of the research presented at INSAR 2019 this year. I am grateful to Drs. Joseph Buxbaum and Emily Jones who chaired the scientific program, as well as the members of the newly formed executive program committee, who helped make strategic decisions about engaging new key stakeholders and increasing neuroscience representation in this meeting. Special thanks to the INSAR board for the guidance and support, the many reviewers for their commitment to assure high quality of content, and the committees who were responsible for the special interest groups, awards, luncheons, and much more. My sincere gratitude to Jennifer Gentry of INSAR and Joe Dymek of ConferenceDirect for making this meeting possible, and assuring a smooth experience for diverse delegates. The 2019 INSAR local community conference is also in Montreal this year. It will highlight both speakers from the INSAR annual meeting, as well as researchers and clinicians from Quebec and their Canadian and international collaborators. Thank you to the many organizations which provided funding for this meeting, my co-chair of the local community conference, Dr Mayada Elsabbagh, for her invaluable insights and support, as well as Dr. Eve-Marie Quintin, and the local advisory board, a diverse group of stakeholders, who advised on content and planning. We extend a warm welcome to you, and hope you will enjoy a stimulating scientific meeting, have the opportunity to network with your international colleagues, and experience this vibrant city with its unique architecture, exhilarating arts scene, and innovating food experience. Sincerely, Evdokia Anagnostou, MD INSAR 2019 Meeting Chair INSAR 2019 is the Annual Meeting of the International Society for Autism Research (INSAR). 2 SCIENTIFIC PROGRAM Welcome to the International Society for Autism Research (INSAR) 2019 Annual Meeting in Montréal, Québec, Canada. As your scientific co-program chairs, it has been our privilege to thoughtfully curate the exchange of the latest scientific progress from autism researchers around the world. WELCOME We hope that you notice that we made a significant commitment to enhance under-represented research disciplines at the meeting. This year, you can expect to see expanded content in biological and medical sciences, and neuroscience more broadly, adding to the already excellent work in psychology and other fields. To build a robust program, we added additional topic areas for submissions and increased the number of panels and keynote speakers. High-quality presentations across all key areas of autism research are essential to the success of the meeting. We ensured broad scientific excellence by forming an Executive Scientific Program Committee of senior autism researchers to determine the gaps in science, actively solicit keynotes and panel participants in these areas, and provide final review for top panels and oral sessions. We also launched an initiative to ensure that panel proposals, while continuing to address cutting edge themes in autism research, also reflect a diversity of viewpoints and/or approaches, as well as diversity in other domains, including gender, geography, ethnicity and career stage. The updates to the expanded call for abstracts were well received by scientists, which was proven by the over 2,000 submissions we received this year. After a strenuous review process, over 1,800 posters, oral and panels were accepted that will represent research from over 50 countries across the globe. Our keynote speakers, Kathryn Roeder, Jason Lerch, Elizabeth Berry-Kravis and Vikram Patel, will enrich the meeting by offering their knowledge on genetics, neuroimaging, neurobiology, clinical trials and global health in autism and associated disorders. We are grateful to the members of the INSAR Board, Executive Scientific Program Committee and Jennifer Gentry, INSAR Administrative Director, for their hard work and perseverance as we worked through the growing pains of expanding the science represented at the meeting and restructuring the review process. It was a great honor to help organize the scientific program that presents the latest research and findings in the field of autism and hope our inclusion of diverse research ensures that INSAR remains the single place to go for information about autism advances. We hope you take advantage of the opportunity to meet and brainstorm with your colleagues and bring new ideas home with you that will inspire new research to improve the quality of lives for people with autism and their families. Joseph D. Buxbaum, PhD Emily Jones, PhD INSAR 2019 Scientific Program Co-Chair INSAR 2019 Scientific Program Co-Chair 3 PRESIDENT’S WELCOME It is my pleasure to welcome you to Montreal for the 2019 Annual Meeting of the International Society for Autism Research (INSAR). The INSAR Annual Meeting is the only conference worldwide that brings together thousands of scientists who study autism from a range of disciplines, alongside policy makers, practitioners, autistic people and their families, to learn about latest research, share new ideas, and strengthen or create new collaborations. I hope you have a wonderful few days, and you leave inspired by what you learn and with a sense of how we are all working together to improve the lives of autistic people, through better understanding. I would like to thank the 2019 Meeting Chair, Evdokia Anagnostou, who in addition to the responsibility of the logistics of the Annual Meeting is responsible for putting together the terrific INSAR local community conference held prior to INSAR 2019. She and the local community conference co-chair, Mayada Elsabbagh, worked with a diverse
Recommended publications
  • House Bill 1306 Industry, Business and Labor January 19, 2021, 2:45

    House Bill 1306 Industry, Business and Labor January 19, 2021, 2:45

    House Bill 1306 Industry, Business and Labor January 19, 2021, 2:45 p.m. Good Morning Chairman Weisz and members of the House Human Services Committee. My name is Molly Howell and I am the Immunization Director of for the North Dakota Department of Health. I do not have testimony for HB1306 but want to let you know I am available virtually to answer questions, if needed. Additionally, attached is a list of studies that have been previously published regarding vaccines, autism and SIDS. Thank You. 1 Vaccine-Related Science: Autism and SIDS No Causal Association Found Autism Literature Reviews: Autism and Vaccines 1. Measles, Mumps, Rubella Vaccination and Autism: A Nationwide Cohort Study PDF available here Annals of Internal Medicine March 2019 The study strongly supports that MMR vaccination does not increase the risk for autism, does not trigger autism in susceptible children, and is not associated with clustering of autism cases after vaccination. It adds to previous studies through significant additional statistical power and by addressing hypotheses of susceptible subgroups and clustering of cases. 2. Autism Occurrence by MMR Vaccine Status Among US Children With Older Siblings With and Without Autism http://jama.jamanetwork.com/article.aspx?articleid=2275444 The Journal of the American Medical Association April 2015 In this large sample of privately insured children with older siblings, receipt of the MMR vaccine was not associated with increased risk of ASD, regardless of whether older siblings had ASD. These findings indicate no harmful association between MMR vaccine receipt and ASD even among children already at higher risk for ASD.
  • May 9-12 Rotterdam Netherlands

    May 9-12 Rotterdam Netherlands

    2018 ANNUAL MEETING MAY 9-12 ROTTERDAM NETHERLANDS PROGRAM BOOK www.autism-insar.org INSAR 2018 Sponsors We thank the following organizations for their generous support of the INSAR Annual Meeting. Platinum Sponsor Level Gold Sponsor Level Silver Sponsor Level Autism Science Foundation Hilibrand Foundation Nancy Lurie Marks Family Foundation TABLE OF CONTENTS Sponsorship .................................Inside Front Cover TABLE OF CONTENTS Special Interest Groups Schedule .......................... 6 Speaker Ready Room ............................................ 6 De Doelen Floor Plans ........................................ 7-9 Meeting Information Schedule-At-A-Glance .................................... 10-12 In-Conjunction Events .................................... 13-14 Keynote Speakers .............................................. 15 Awardees ..................................................... 16-19 INSAR MISSION Acknowledgments .......................................... 20-21 STATEMENT To promote the highest quality INSAR Summer Institute .................................... 22 research in order to improve the Abstract Author Index ...................................... 134 lives of people affected by autism. General Information .......................................... 208 Exhibitors ....................................................... 210 Strategic Initiatives Setting the Bar: Increase the quality, AM diversity and relevance of research promoted through annual meetings, journal, Keynote Address ...............................................
  • Association Between Maternal Use of Folic Acid Supplements and Risk of Autism Spectrum Disorders in Children

    Association Between Maternal Use of Folic Acid Supplements and Risk of Autism Spectrum Disorders in Children

    ORIGINAL CONTRIBUTION Association Between Maternal Use of Folic Acid Supplements and Risk of Autism Spectrum Disorders in Children ˚ ´ Pal Suren, MD, MPH Importance Prenatal folic acid supplements reduce the risk of neural tube defects Christine Roth, MSc in children, but it has not been determined whether they protect against other neu- Michaeline Bresnahan, PhD rodevelopmental disorders. Margaretha Haugen, PhD Objective To examine the association between maternal use of prenatal folic acid supplements and subsequent risk of autism spectrum disorders (ASDs) (autistic disor- Mady Hornig, MD der, Asperger syndrome, pervasive developmental disorder–not otherwise specified Deborah Hirtz, MD [PDD-NOS]) in children. Kari Kveim Lie, MD Design, Setting, and Patients The study sample of 85 176 children was derived from the population-based, prospective Norwegian Mother and Child Cohort Study W. Ian Lipkin, MD (MoBa). The children were born in 2002-2008; by the end of follow-up on March 31, Per Magnus, MD, PhD 2012, the age range was 3.3 through 10.2 years (mean, 6.4 years). The exposure of Ted Reichborn-Kjennerud, MD, PhD primary interest was use of folic acid from 4 weeks before to 8 weeks after the start of pregnancy, defined as the first day of the last menstrual period before conception. Synnve Schjølberg, MSc Relative risks of ASDs were estimated by odds ratios (ORs) with 95% CIs in a logistic George Davey Smith, MD, DSc regression analysis. Analyses were adjusted for maternal education level, year of birth, and parity. Anne-Siri Øyen, PhD Main Outcome Measure Specialist-confirmed diagnosis of ASDs. Ezra Susser, MD, DrPH Results At the end of follow-up, 270 children in the study sample had been diag- Camilla Stoltenberg, MD, PhD nosed with ASDs: 114 with autistic disorder, 56 with Asperger syndrome, and 100 with PDD-NOS.
  • Lower Autism Risk with Folic Acid Supplements in Pregnancy 12 February 2013

    Lower Autism Risk with Folic Acid Supplements in Pregnancy 12 February 2013

    Lower autism risk with folic acid supplements in pregnancy 12 February 2013 Women who took folic acid supplements in early of folic acid supplements in the mother during pregnancy almost halved the risk of having a child pregnancy and a reduced risk of childhood autism. with autism. Beginning to take folic acid supplements later in pregnancy did not reduce the "The study does not prove that folic acid risk. This is shown in new findings from the ABC supplements can prevent childhood autism. Study and Norwegian Mother and Child Cohort However, the findings are so apparent that they Study published in the Journal of The American constitute a good argument to further examine Medical Association (JAMA). possible causal mechanisms. It should also be ascertained whether folic acid is associated with a Women who took folic acid supplements from four reduced risk of other brain disorders in children," weeks before conception to eight weeks into says Surén. pregnancy had a 40 per cent lower risk of giving birth to children with childhood autism (classic Emphasises the importance of folic acid autism). Use of folic acid supplements midway supplements through pregnancy (week 22) had no effect. The results support the Norwegian Directorate of The findings only apply to a lower risk of childhood Health's recommendations for folic acid autism, the most severe form of autism. The supplements during pregnancy and emphasise the results show no reduction in the risk of atypical or importance of starting early—preferably before unspecific autism. The study also investigated the conception. prevalence of Asperger syndrome, but the number of examined children was too low to give a reliable Method result.
  • The Joy of Autism: Part 2

    The Joy of Autism: Part 2

    However, even autistic individuals who are profoundly disabled eventually gain the ability to communicate effectively, and to learn, and to reason about their behaviour and about effective ways to exercise control over their environment, their unique individual aspects of autism that go beyond the physiology of autism and the source of the profound intrinsic disabilities will come to light. These aspects of autism involve how they think, how they feel, how they express their sensory preferences and aesthetic sensibilities, and how they experience the world around them. Those aspects of individuality must be accorded the same degree of respect and the same validity of meaning as they would be in a non autistic individual rather than be written off, as they all too often are, as the meaningless products of a monolithically bad affliction." Based on these extremes -- the disabling factors and atypical individuality, Phil says, they are more so disabling because society devalues the atypical aspects and fails to accommodate the disabling ones. That my friends, is what we are working towards -- a place where the group we seek to "help," we listen to. We do not get offended when we are corrected by the group. We are the parents. We have a duty to listen because one day, our children may be the same people correcting others tomorrow. In closing, about assumptions, I post the article written by Ann MacDonald a few days ago in the Seattle Post Intelligencer: By ANNE MCDONALD GUEST COLUMNIST Three years ago, a 6-year-old Seattle girl called Ashley, who had severe disabilities, was, at her parents' request, given a medical treatment called "growth attenuation" to prevent her growing.
  • An Enlightening Conversation on Autism « Dana Foundation

    An Enlightening Conversation on Autism « Dana Foundation

    An Enlightening Conversation on Autism « Dana Foundation https://danablog.org/2016/02/10/an-enlightening-conversation-o... An Enlightening Conversation on Autism FEBRUARY 10, 2016 An hour before a program titled “The Spectrum” began, featured participant David Amaral, Ph.D., complained that in the weeks leading up to the event, he had had trouble getting his hands on Snow Cake, a 2007 film in which Sigourney Weaver plays a high-functioning autistic woman. “I tried Netflix, Amazon Prime, and Hulu, and couldn’t find it anywhere,” said Amaral. “But I was eventually able to find the DVD on Amazon—and liked it very much.” That’s high praise coming from one of the nation’s foremost researchers on autism. Amaral, UC Davis Distinguished Professor of Psychiatry and Neuroscience and the Beneto Foundation chair, and founding research director of the M.I.N.D. Institute, and Weaver, an acclaimed actress, film producer, and noted environmentalist, discussed autism to a sold-out audience at the Rubin Museum of Art in Manhattan. Lyn Hughes Photography, courtesy of the Rubin Museum of Art. The program—the second in an annual Brainwave series that runs through April—opened with a clip from Snow Cake [here’s a short clip via YouTube]. Despite a review in the New York Times that called Weaver’s performance “convincingly precise,” few in the audience had seen or heard of the film. Brain- centric films, even when they are lauded for extraordinary performances (Concussion with Will Smith and Still Alice with Julianne Moore come to mind), rarely live up to box office expectations.
  • Message from David Amaral, Scientific Director of Autism Brainnet New Technique Provides Deeper View of ​Brain Development

    Message from David Amaral, Scientific Director of Autism Brainnet New Technique Provides Deeper View of ​Brain Development

    December 9, 2020 Message from David Amaral, Scientific Director of Autism BrainNet What a year! Most people would agree that it has been a particularly difficult year with all of the turmoil in our daily lives, in our politics, and the many injustices in our society. I’m writing this over the Thanksgiving weekend and I’m sure many are wondering whether there is anything in 2020 to be thankful for. My answer is a resounding Yes. Read more SCIENCE New technique provides deeper view of ​brain development Knowing how and when different brain cell types emerge during brain development may help us understand how the brain develops and identify changes that contribute to neurodevelopmental conditions. A new study applied a novel technique to postmortem human brain tissue to provide insights into brain development. Read more about the study Researchers uncover a new way that genes are regulated in the autism brain Hundreds of genes have been linked to autism, but these genes explain only a small portion of cases. A recent study explored the function of circular RNAs, and their effect on gene activity, in the brain of people who have autism. Read more about the study MEET OUR TEAM A conversation with Alicja Omanska, tissue coordinator of Autism BrainNet Sacramento node We recently spoke with Alicja Omanska, tissue coordinator for Autism BrainNet at the UC Davis MIND Institute in Sacramento, CA, to learn more about her research, her role with Autism BrainNet and the importance of advancing autism research. Read the interview NEW COLLABORATIONS Autism BrainNet welcomes the Prader-Willi Syndrome Association and the Families SCN2a Foundation, our newest family group partners.
  • Autism Spectrum Conditions Affect Preferences in Valued Personal Possessions

    Autism Spectrum Conditions Affect Preferences in Valued Personal Possessions

    This is a repository copy of Autism spectrum conditions affect preferences in valued personal possessions. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/130206/ Version: Accepted Version Article: Spikins, Penny orcid.org/0000-0002-9174-5168, Wright, Barry John Debenham orcid.org/0000-0002-8692-6001 and Scott, Callum (2018) Autism spectrum conditions affect preferences in valued personal possessions. Evolutionary Behavioral Sciences. pp. 99-112. ISSN 2330-2925 https://doi.org/10.1037/ebs0000105 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Running head: AUTISM AND VALUED PERSONAL POSSESSIONS Autism spectrum conditions affect preferences in valued personal possessions Penny Spikins, Barry Wright and Callum Scott University of York Author Note Penny Spikins, Department of Archaeology, University of York, UK, Barry Wright, Department of Health Sciences, University of York, UK Callum Scott, Department of Archaeology, University of York, UK This research was supported in part by grants from the Creativity Priming Fund, University of York and the Sir John Templeton Foundation, and the survey was carried out with assistance from the National Autistic Society, UK.
  • Campbell-Smith Mead Autism Decision.Pdf

    Campbell-Smith Mead Autism Decision.Pdf

    In the United States Court of Federal Claims OFFICE OF SPECIAL MASTERS (E-Filed: March 12, 2010) No. 03-215V TO BE PUBLISHED ____________________________________ GEORGE and VICTORIA ) MEAD, Parents of ) Omnibus Autism Proceeding; WILLIAM P. MEAD, ) Test Case; Petitioners’ Second ) Theory of General Causation; Petitioners, ) Failure to Prove that ) Thimerosal-Containing v. ) Vaccines Cause Autism ) SECRETARY OF HEALTH AND ) HUMAN SERVICES, ) ) Respondent. ) ____________________________________) Thomas Powers, Portland, OR, for petitioners. Lynn Ricciardella, United States Department of Justice, Washington, DC, for respondent. DECISION1 1 Vaccine Rule 18(b) provides that all of the decisions of the special masters will be made available to the public unless an issued decision contains trade secrets or commercial or financial information that is privileged or confidential, or the decision contains medical or similar information the disclosure of which clearly would constitute an unwarranted invasion of privacy. When a special master issues a decision or substantive order, the parties have 14 days within which to move for the redaction of privileged or confidential information before the document’s public disclosure. In this case, petitioners have elected to waive the 14-day period afforded for redaction requests prior to the public disclosure of an issued decision. In Petitioners’ Notice to Waive the 14-Day Waiting Period as Defined in Vaccine Rule 18(b) (Petitioners’ Waiver Notice), petitioners state that “none of the information they have furnished in their case is ‘private’ information.” Petitioners’ Waiver Notice at 1, filed on 1/26/10. Petitioners add that the “disclosure of any or all information they have furnished (continued...) CAMPBELL-SMITH, Special Master On January 29, 2003, George and Victoria Mead (petitioners or the Meads), as parents of William P.
  • Behavioral Profiles of Clinically Referred Children with Intellectual Giftedness

    Behavioral Profiles of Clinically Referred Children with Intellectual Giftedness

    Hindawi Publishing Corporation BioMed Research International Volume 2013, Article ID 540153, 7 pages http://dx.doi.org/10.1155/2013/540153 Research Article Behavioral Profiles of Clinically Referred Children with Intellectual Giftedness Fabian Guénolé,1 Jacqueline Louis,2 Christian Creveuil,3,4 Jean-Marc Baleyte,1,4 Claire Montlahuc,2 Pierre Fourneret,2,5 and Olivier Revol2 1 CHUdeCaen,ServicedePsychiatriedel’Enfantetdel’Adolescent,avenueClemenceau,14033CaenCedex9,France 2 Hospices Civils de Lyon, Service Hospitalo-Universitaire de Psychiatrie de l’Enfant et de l’Adolescent, Hopitalˆ Femme-Mere-Enfant,` 59boulevardPinel,69500Bron,France 3 CHU de Caen, Unite´ de Biostatistiques et de Recherche Clinique, avenue Clemenceau, 14033 Caen Cedex 9, France 4 UniversitedeNormandie,Facult´ edeM´ edecine,´ avenue de la Coteˆ de Nacre, 14032 Caen Cedex 5, France 5 Universite´ Claude Bernard Lyon-1, FacultedeM´ edecine´ Lyon Est, 8 avenue Rockefeller, 69373 Lyon Cedex 8, France Correspondence should be addressed to Fabian Guenol´ e;´ guenole [email protected] Received 21 April 2013; Revised 15 June 2013; Accepted 15 June 2013 Academic Editor: Harold K. Simon Copyright © 2013 Fabian Guenol´ e´ et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. It is common that intellectually gifted children—that is, children with an IQ ≥ 130—are referred to paediatric or child neuropsychiatry clinics for socio-emotional problems and/or school underachievement or maladjustment. These clinically-referred children with intellectual giftedness are thought to typically display internalizing problems (i.e., self-focused problems reflecting overcontrol of emotion and behavior), and to be more behaviorally impaired when “highly” gifted (IQ ≥ 145) or displaying developmental asynchrony (i.e., a heterogeneous developmental pattern, reflected in a significant verbal-performance discrepancy on IQ tests).
  • Environmental Health Issue

    Environmental Health Issue

    FIFTH EDITION 2006, Volume 45 R5 Environmental Health and Autism In thIs Issue: Time To GeT a Grip By martha r. Herbert, m.D., ph.D. Beyond Behavior—Biomedical Diagnoses in Autism spectrum Disorders By Margaret L. Bauman, M.D. transforming the Public Debate on neurotoxicants By Elise Miller, M.Ed. ADVERTISEMENT ADVERTISEMENT Autism does not have to be a life sentence You’re not about to give up on your child. Neither Are We. Since , the Autism Treatment Center of America™ has provided innovative training programs for parents and professionals caringifor children challenged by Autism Spectrum Disorders and related developmental difficulties. • Practical Tools • Powerful Results • Limitless Hope c Help your child improve in all areas of over p learning, development, communication and hoto skill acquisition. : © W I Join us for our internationally-acclaimed ll T ERR Son-Rise Program® Start-Up, a y comprehensive weeklong training program for parents and professionals. We don’t put limits on the possibilities for your child. Free 25-Minute Initial Call 877-766-7473 We’ll give you the keys to unlock their world. HOME OF THE SON-RISE PROGRAM® SINCE 1983 South Undermountain Road Sheffield, MA - USA Telephone: -- • E-mail: [email protected] www.autismtreatment.com Copyright © 2006 by The Option Institute & Fellowship. All rights reserved. 02.06-6 CONTENTS December 2006 page 18 SpOTlIGHT Time to Get A Grip By marTHa r. HerBerT, m.D., pH.D. Does an environmental role in autism make sense? How do we decide? And if environment is involved in autism, what do we do about it? These are challenging questions.
  • Sensitivity and Specificity of Early Screening for Autism

    Sensitivity and Specificity of Early Screening for Autism

    BJPsych Open (2019) 5, e41, 1–8. doi: 10.1192/bjo.2019.34 Sensitivity and specificity of early screening for autism Pål Surén, Alexandra Saasen-Havdahl, Michaeline Bresnahan, Deborah Hirtz, Mady Hornig, Catherine Lord, Ted Reichborn-Kjennerud, Synnve Schjølberg, Anne-Siri Øyen, Per Magnus, Ezra Susser, W. Ian Lipkin and Camilla Stoltenberg Background (95% CI 58–79) for ASD without phrase speech and 34% (95% CI – Early identification and diagnosis is beneficial for children with 29 40) for ASD with phrase speech. Specificity was then reduced – autism spectrum disorder (ASD). Universal early screening is to 89% (95% CI 89 90). recommended by many experts, but disputed because evidence is limited, and sensitivity and specificity in general populations Conclusions are largely unknown. Early ASD screening with a parent checklist had low sensitivity. It identified mainly individuals with ASD with significant develop- Aims mental delay and captured very few children with ASD with To estimate the sensitivity and specificity of early population- cognitive skills in the normal range. Increasing sensitivity was not based screening for ASDs. possible without severely compromising specificity. Method Declaration of interest The study was based on the Norwegian Mother and Child Cohort C.L. receives royalty for the Social Communication Study. The 36-month cohort questionnaire included the Social Questionnaire, which she has co-authored. Communication Questionnaire (SCQ), a 40-item screening instrument for ASD. Keywords Results Autistic spectrum disorders; developmental disorders; A total of 58 520 mothers (58%) responded to the questionnaire. epidemiology. By the end of follow-up on 31 December 2015, 385 (0.7%) indi- viduals with ASD had been identified among the responders’ Copyright and usage children.